Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa

Christos C. Zouboulis, Hendrik Hansen, Raffaele Dante Caposiena Caro, Giovanni Damiani, Isabelle Delorme, José Carlos Pascual, Ziad Reguiai, Anastasia Trigoni, Eva Vilarrasa, Fernando Alfageme Roldán

Research output: Contribution to journalArticle

Abstract

Background: Adalimumab is the only approved compound for the treatment of adult patients with moderate-to-severe hidradenitis suppurativa (HS) who did not respond to a systemic classical treatment. Despite its significant short- and long-term efficacy, a percentage of patients do not respond sufficiently. Moreover, some primary responders experience a response loss with time. Objective: To analyse the effectiveness of adalimumab dose intensification in HS patients. Methods: A case series of adalimumab 80 mg/week subcutaneously (s.c.) compassionate use in patients with HS, who did not respond sufficiently or in primary responders with progressive response loss to the registered adalimumab dose of 40 mg/week s.c. Patients were collected and evaluated retrospectively. Patients' data were extracted from medical records. Results: The 14 patients collected were Caucasian with HS of Hurley stage II-III and moderate or severe International HS Severity Score System (IHS4) stage. Adalimumab dose intensification significantly improved IHS4 score, Pain Index, HS-Physician Global Assessment, pain, and Cardiff Dermatology Life Quality Index. Two young female patients with HS and Crohn's disease developed psoriatic lesions during the treatment with adalimumab 80 mg/week s.c. Conclusion: An enhanced level of effectiveness was assessed in the majority of the HS patients treated with adalimumab dose intensification (80 mg/week s.c.). Larger studies are required to evaluate this observation.

Original languageEnglish
Pages (from-to)25-30
Number of pages6
JournalDermatology
Volume236
Issue number1
DOIs
Publication statusPublished - 2020
Externally publishedYes

    Fingerprint

Keywords

  • Acne inversa
  • Adalimumab
  • Hidradenitis suppurativa
  • Intensification
  • Treatment

ASJC Scopus subject areas

  • Dermatology

Cite this

Zouboulis, C. C., Hansen, H., Caposiena Caro, R. D., Damiani, G., Delorme, I., Pascual, J. C., Reguiai, Z., Trigoni, A., Vilarrasa, E., & Roldán, F. A. (2020). Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa. Dermatology, 236(1), 25-30. https://doi.org/10.1159/000503606